title: Antihyperglycemic effect of umbelliferone in streptozotocin-diabetic rats.
abstract: The present study was designed to investigate the antihyperglycemic effect of Umbelliferone (UMB) in normal and streptozotocin (STZ)-diabetic rats. Diabetes was induced in adult male albino rats of the Wistar strain, weighing 180-200 g, by administration of STZ (40 mg/kg of body weight) intraperitoneally. Diabetic rats showed an increase in levels of blood glucose and glycosylated hemoglobin (HbA(1c)) and activities of gluconeogenic enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase, and a decrease in levels of plasma insulin, hemoglobin (Hb), and liver glycogen and activities of glucokinase and glucose-6-phosphate dehydrogenase. Intraperitoneal administration of UMB (10, 20, and 30 mg/kg of body weight) and glibenclamide (600 micro g/kg of body weight) in 10% dimethyl sulfoxide dissolved in water, for 45 days, produced significantly decreased levels of blood glucose and HbA(1c) and activities of glucose-6-phosphatase and fructose-1,6-bisphosphatase, while elevating levels of plasma insulin, Hb, and liver glycogen and activities of glucokinase and glucose-6-phosphate dehydrogenase to near normal levels in STZ-diabetic rats when compared with normal control rats. Normal rats treated with UMB (30 mg/kg of body weight) also showed a significant effect on glycemic control. Thus, our results show that UMB at 30 mg/kg of body weight possesses a promising antihyperglycemic effect that is comparable with glibenclamide.
authors.affiliation: Department of Biochemistry, Faculty of Science, Annamalai University, Annamalainagar, Tamilnadu, India.
authors.forename: B
authors.initials: B
authors.lastname: Ramesh
authors.forename: K V
authors.initials: KV
authors.lastname: Pugalendi
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D006597:Fructose-Bisphosphatase / Q000378:metabolism; D005941:Glucokinase / Q000378:metabolism; D005952:Glucose-6-Phosphatase / Q000378:metabolism; D005954:Glucosephosphate Dehydrogenase / Q000378:metabolism; D005905:Glyburide / Q000008:administration & dosage; D006442:Glycated Hemoglobin / Q000032:analysis; D006003:Glycogen / Q000032:analysis; D006029:Glycosuria / Q000188:drug therapy; D006454:Hemoglobins / Q000032:analysis; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D007668:Kidney / Q000201:enzymology; D008099:Liver / Q000737:chemistry / Q000201:enzymology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D014468:Umbelliferones / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D006597:Fructose-Bisphosphatase; D005941:Glucokinase; D005952:Glucose-6-Phosphatase; D005954:Glucosephosphate Dehydrogenase; D005905:Glyburide; D006442:Glycated Hemoglobin; D006003:Glycogen; D006454:Hemoglobins; D007004:Hypoglycemic Agents; D007328:Insulin; D014468:Umbelliferones; C031477:7-hydroxycoumarin